BELGRADE, Mont., April 01, 2019 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the fourth quarter and year ended December 31, 2018.

Fourth Quarter 2018 Financial Highlights and Recent Announcements:

  • Revenue for the fourth quarter of 2018 was $18.3 million, compared to $19.3 million for the same prior year period
  • Net loss incurred in the fourth quarter of 2018 was $56.7 million, compared to a net loss of $28.4 million for the same prior year period
  • Excluding non-cash impairment charges and inventory reserves, net loss in the fourth quarter of 2018 was $4.2 million, compared to a net loss of $8.6 million for the same prior year period
  • Non-GAAP Adjusted EBITDA for the fourth quarter of 2018 was $1.3 million, compared to a loss of $0.9 million for the same prior year period
  • OrbiMed Advisors agreed to amend and restate the credit facility to allow for an additional debt invest up to $10 million to support the Company’s working capital needs
  • As previously announced, the Company appointed Ronald Berlin as Vice President & Chief Operations Officer, Greg Jensen as Vice President, Finance and Interim Chief Financial Officer and five senior sales executives, and has commenced a search for a new Chief Executive Officer

Greg Jensen, VP, Finance and Interim CFO of Xtant Medical, said, “Our success in executing cost reductions and revitalizing our sales channel has allowed us to make significant progress in repositioning the Company. The appointment of several proven sales leaders to our team is expected to further advance and expand our sales capabilities and potentially support the introduction of new products in late 2019. With OrbiMed’s recent investment of $10 million in additional debt capital, we have made progress toward strengthening our capital structure and improving our financial flexibility. We appreciate OrbiMed’s continued support and confidence in Xtant’s growth potential. We believe we have a strong foundation on which to achieve the Company’s long-term objectives and remain committed to creating value for patients and shareholders.”

Fourth Quarter and Full Year 2018 Financial Results

Fourth quarter 2018 revenue was $18.3 million, compared to $19.3 million for the same period in 2017. Full year 2018 revenue was $72.2 million, compared to $82.6 million for 2017. The decreases occurred primarily due to the decrease in sales in the spinal hardware implant product line.

Gross profit for the fourth quarter of 2018 was 39.7%, compared to 53.2% for the same period in 2017 and was 60.2% for 2018, compared to 60.6% in 2017. In the fourth quarter of 2018 and 2017, the Company increased its inventory reserve by $4.4 million and $2.2 million, respectively, primarily due to excess inventory in the spinal implant product line. Excluding the inventory reserve adjustments in 2018 and 2017, gross profit would have been 63.7% and 64.6% for the fourth quarter, respectively, and 66.3% and 63.3%, for the full year, respectively.

Operating expenses for the fourth quarter of 2018 were $62.0 million, compared to $37.4 million for the fourth quarter of 2017, and were $103.6 million in 2018 compared to $87.9 million in 2017. In the fourth quarter of 2018 and 2017, the Company incurred non-cash impairment charges to goodwill and intangibles attributed to the X-Spine acquisition totaling $48.1 million and $17.6 million, respectively. Excluding the non-cash impairment charges, operating expenses were $13.8 million in the fourth quarter of 2018 compared to $19.8 million in the fourth quarter of 2017, and $55.4 million in 2018 compared to $70.3 million in 2017. These decreases were primarily attributable to lower commission expense as a result of lower revenue during 2018, a decrease in general and administrative expenses, and cost reduction initiatives to consolidate facilities.

Fourth quarter 2018 net loss was $56.7 million, or $4.31 per share, compared to fourth quarter 2017 net loss of $28.4 million, or $18.77 per share. Net loss for 2018 was $70.1 million, or $5.97 per share, compared to $52.4 million, or $34.76 per share, in 2017. Excluding the non-cash impairment charges and the inventory reserve charges, the net loss was $4.2 million, or $0.32 per share, in the fourth quarter of 2018, compared to $8.6 million, or $5.70 per share, for the fourth quarter of 2017, and $17.6 million, or $1.50 per share, in 2018 compared to $32.6 million, or $21.64 per share, in 2017.

Non-GAAP Adjusted EBITDA for the fourth quarter of 2018 was $1.3 million compared to a loss of $0.9 million for the same period of 2017. Non-GAAP Adjusted EBITDA for 2018 was $4.7 million, compared to $0.5 million for 2017. The Company defines Adjusted EBITDA as net income/loss from operations before depreciation, amortization and interest expense, and as further adjusted to add back in or exclude, as applicable, non-cash special charges, provision for losses on inventory, non-cash impairment charges, non-cash compensation, change in warrant derivative liability, separation related expenses, litigation reserve, facility consolidation costs and restructuring expenses. A calculation and reconciliation of non-GAAP Adjusted EBITDA to net loss can be found in the attached financial tables.

Amendments to Credit Facility and Debt Capital Investment

On March 29, 2019, the Company and its lenders entered into a Second Amended and Restated Credit Agreement, which, among other provisions, increased availability by an additional $10 million via an incremental delayed draw term loan, extended the maturity date to March 31, 2021 and the period during which no interest accrues from December 31, 2018 until March 31, 2020, and replaced the Minimum Consolidated EBITDA and Consolidated Senior Leverage Ratio Covenants with a new Minimum Revenue Covenant, to support the Company’s working capital needs. In connection with new amendment, the Company issued warrants for the purchase of 1.2 million shares of Xtant common stock with an exercise price of $0.01 per share and an expiration date of April 1, 2029, to OrbiMed Royalty Opportunities II, LP and ROS Acquisition Offshore LP, which collectively own approximately 70% of Xtant’s outstanding common stock and are the sole holders of the Company’s outstanding long-term debt under the credit facility.

Conference Call

Xtant Medical will host a webcast and conference call to discuss the fourth quarter and full year 2018 financial results on Monday, April 1, 2019 at 9:00 AM ET. To access the webcast, Click Here. To access the conference call, dial 877-407-6184 within the U.S. or 201-389-0877 outside the U.S. A replay of the call will be available at www.xtantmedical.com, under “Investor Info.”

About Xtant Medical Holdings, Inc.

Xtant Medical Holdings, Inc. (www.xtantmedical.com) is a global medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Xtant people are dedicated and talented, operating with the highest integrity to serve our customers.

™ and ® denote trademarks and registered trademarks of Xtant Medical Holdings, Inc. or its affiliates, registered as indicated in the United States, and in other countries. All other trademarks and trade names referred to in this release are the property of their respective owners.

Non-GAAP Financial Measures

To supplement the Company’s consolidated financial statements prepared in accordance with U.S. generally accepted accounting principles (GAAP), the Company uses certain non-GAAP financial measures in this release, including Adjusted EBITDA, net loss excluding non-cash impairment charges, operating expenses excluding non-cash impairment charges and gross profit excluding inventory reserve adjustments. Reconciliations of the non-GAAP financial measures used in this release to the most comparable GAAP measures for the respective periods can be found in tables later in this release. The Company’s management believes that the presentation of these measures provides useful information to investors. These measures may assist investors in evaluating the Company’s operations, period over period. Management uses the non-GAAP measures in this release internally for evaluation of the performance of the business, including the allocation of resources. Investors should consider non-GAAP financial measures only as a supplement to, not as a substitute for or as superior to, measures of financial performance prepared in accordance with GAAP.

Important Cautions Regarding Forward-looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements that are predictive in nature, that depend upon or refer to future events or conditions, or that include words such as ‘‘expects,’’ ‘‘anticipates,’’ ‘‘intends,’’ ‘‘plans,’’ ‘‘believes,’’ ‘‘estimates,’’ “continue,” “future,” ‘‘will,’’ “potential” similar expressions or the negative thereof, and the use of future dates. The Company cautions that its forward-looking statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors, including, among others: the Company’s future operating results and financial performance; the ability to increase or maintain revenue; the ability to remain competitive; the ability to innovate and develop new products; the effect of recent management changes and the ability to engage and retain qualified personnel; government and third-party coverage and reimbursement for Company products; the ability to obtain and maintain regulatory approvals and comply with government regulations; the effect of product liability claims and other litigation to which the Company may be subject; the effect of product recalls and defects; timing and results of clinical studies; the ability to obtain and protect Company intellectual property and proprietary rights and operate without infringing the rights of others; the ability to service Company debt and comply with debt covenants; the ability to raise additional financing and other factors. Additional risk factors are contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017 filed with the Securities and Exchange Commission (SEC) on April 2, 2018 and subsequent SEC filings by the Company, including without limitation its most recent Quarterly Report on Form 10-Q for the quarter ended September 30, 2018 filed with the SEC on November 14, 2018 and its Annual Report on Form 10-K for the year ended December 31, 2018 anticipated to be filed with the SEC. Investors are encouraged to read the Company’s filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The Company undertakes no obligation to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by this cautionary statement.

Investor Relations Contact

David Carey
Lazar Partners Ltd.
Ph: 212-867-1762
Email: dcarey@lazarpartners.com

 
XTANT MEDICAL HOLDINGS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except number of shares and par value)
 
 As of December
31, 2018		 As of December
31, 2017
    
ASSETS   
Current Assets:   
Cash and cash equivalents$6,797  $2,856 
Trade accounts receivable, net of allowance for doubtful accounts of $2,140 and $2,135, respectively 9,990   12,714 
Inventories, net 17,301   22,423 
Prepaid and other current assets 589   1,706 
Total current assets 34,677   39,699 
    
Property and equipment, net 7,174   9,913 
Goodwill 3,205   41,535 
Intangible assets, net 573   13,826 
Other assets 793   732 
    
Total Assets$46,422  $105,705 
    
LIABILITIES & STOCKHOLDERS' EQUITY (DEFICIT)   
Current Liabilities:   
Accounts payable$6,465  $9,316 
Accounts payable - related party -   160 
Accrued liabilities 5,150   15,845 
Warrant derivative liability 10   131 
Current portion of capital lease obligations 426   366 
Total current liabilities 12,051   25,818 
    
Long-term Liabilities:   
Capital lease obligation, less current portion 204   624 
Long-term convertible debt, less issuance costs -   70,853 
Long-term debt, less issuance costs 77,939   67,109 
Total Liabilities 90,194   164,404 
    
Stockholders' Equity (Deficit)   
Preferred stock, $0.000001 par value; 10,000,000 shares authorized; no shares issued and outstanding -   - 
Common stock, $0.000001 par value; 50,000,000 shares authorized; 13,172,179 shares issued and outstanding as of December 31, 2018 and 1,514,899 shares issued and outstanding as of December 31, 2017 -   - 
Additional paid-in capital 171,273   86,247 
Accumulated deficit (215,045)  (144,946)
Total Stockholders’ Equity (Deficit) (43,772)  (58,699)
    
Total Liabilities & Stockholders’ Equity (Deficit)$46,422  $105,705 


XTANT MEDICAL HOLDINGS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited, in thousands, except number of shares and per share amounts)
 
 Three Months Ended December 31,
 Twelve Months Ended December 31,
  2018   2017   2018   2017 
Revenue       
Orthopedic product sales$18,192  $19,528  $71,814  $82,513 
Other revenue 70   (196)  389   99 
Total revenue 18,262   19,332   72,203   82,612 
        
Cost of sales 11,006   9,039   28,717   32,511 
        
Gross profit 7,256   10,293   43,486   50,101 
        
Gross profit % 39.7%  53.2%  60.2%  60.6%
        
Operating expenses       
General and administrative 3,330   3,260   12,881   15,246 
Sales and marketing 7,317   9,474   32,059   40,511 
Research and development 523   598   1,702   2,441 
Depreciation and amortization 1,044   1,381   4,118   5,485 
Goodwill & Intangible Asset impairment 48,146   17,586   48,146   17,586 
Restructuring expenses 435   4,680   2,970   4,680 
Separation related expenses 1,078   505   1,568   1,901 
Non-cash consulting expense 108   (132)  120   85 
Total operating expenses 61,981   37,352   103,564   87,935 
        
Loss from operations (54,725)  (27,059)  (60,078)  (37,834)
        
Other Income (Expense)       
Interest expense (1,990)  (4,166)  (10,145)  (14,705)
Change in warrant derivative liability 38   65   121   203 
Other (expense) income (14)  2,740   3   (75)
Total Other (Expense) Income (1,966)  (1,361)  (10,021)  (14,577)
        
        
Net Loss$(56,691) $(28,420) $(70,099) $(52,411)
        
Net loss per share:       
Basic$(4.31) $(18.77) $(5.97) $(34.76)
Dilutive$(4.31) $(18.77) $(5.97) $(34.76)
        
Shares used in the computation:       
Basic 13,158,326   1,514,501   11,740,550   1,507,769 
Dilutive 13,158,326   1,514,501   11,740,550   1,507,769 


XTANT MEDICAL HOLDINGS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited, in thousands)
 
 Year Ended December 31,
  2018   2017 
Operating activities:   
Net loss$(70,099) $(52,411)
Adjustments to reconcile net loss to net cash used in operating activities:   
Depreciation and amortization 6,590   8,409 
Loss on goodwill and intangible impairment and disposal of fixed assets 48,249   21,242 
Non-cash interest 9,848   14,685 
Loss on sale of fixed assets -   10 
Non-cash consulting expense/stock option expense 694   212 
Provision for losses on accounts receivable and inventory 5,120   4,213 
Change in derivative warrant liability (121)  (203)
    
Changes in operating assets and liabilities:   
Trade accounts receivable 2,536   4,747 
Inventories 40   2,122 
Prepaid and other assets 1,055   (460)
Accounts payable (3,011)  (1,637)
Accrued liabilities 311   (1,472)
Net cash provided by (used in) operating activities 1,212   (543)
    
Investing activities:   
Purchases of property and equipment and intangible assets (624)  (1,641)
Proceeds from sale of fixed assets 257   33 
Net cash used in investing activities (367)  (1,608)
    
Financing activities:   
Proceeds from long-term and convertible debt, net of deferred and financing costs -   12,787 
Payments on capital leases (359)  (88)
Net payments on revolving line credit -   (10,448)
Costs associated with private placement and convertible debt conversion (3,356)  - 
Proceeds from equity private placement 6,810   - 
Net proceeds from issuance of stock 1   178 
Net cash provided by financing activities 3,096   2,429 
    
Net change in cash and cash equivalents 3,941   278 
    
Cash and cash equivalents at beginning of period 2,856   2,578 
Cash and cash equivalents at end of period$6,797  $2,856 


XTANT MEDICAL HOLDINGS, INC.
CALCULATION OF NON-GAAP CONSOLIDATED EBITDA AND ADJUSTED EBITDA
AND RECONCILIATION TO NET LOSS FOR THE PERIODS ENDED
DECEMBER 31, 2018 AND 2017
(Unaudited, in thousands)
 
 Three Months Ended December 31, Twelve Months Ended December 31,
  2018   2017   2018   2017 
        
Net Loss$(56,691) $(28,420) $(70,099) $(52,411)
        
Other expense (income) 14   (2,740)  (3)  75 
Depreciation and amortization 1,646   963   6,589   8,394 
Interest expense 1,990   4,166   10,145   14,705 
        
Non-GAAP EBITDA gain (loss)   (53,041)    (26,031)    (53,368)    (29,237)
        
Non-GAAP EBITDA/Total revenue -290.4%  -134.7%  -73.9%  -35.4%
        
NON-GAAP ADJUSTED EBITDA CALCULATION       
Impairment of goodwill and intangible assets and fixed assets 48,146   17,664   48,146   19,445 
Provision for losses on AR and inventory 4,378   2,199   4,378   2,199 
Non-cash compensation 108   (132)  694   85 
Change in warrant derivative liability (38)  (66)  (121)  (203)
Separation related expenses 1,078   505   1,568   1,901 
Litigation reserve 195   -   195   1,342 
Facility consolidation costs (5)  -   42   - 
Dayton transition costs 6   290   199   290 
Restructuring expenses 435   4,680   2,970   4,680 
        
Non-GAAP Adjusted EBITDA gain (loss)$   1,262   $   (891) $   4,703   $   502  
        
Non-GAAP Adjusted EBITDA/Total revenue 6.9%  -4.6%  6.5%  0.6%


XTANT MEDICAL HOLDINGS, INC.
CALCULATION ON NON-GAAP ADJUSTED NET INCOME, NON-GAAP ADJUSTED GROSS PROFIT AND NON-GAAP ADJUSTED OPERATING EXPENSES
AND RECONCILIATION TO GAAP NET INCOME, GAAP GROSS PROFIT AND GAAP OPERATING EXPENSES FOR THE PERIODS ENDING DECEMBER 31,
2018
(Unaudited, in thousands, except number of shares and per share amounts)
 
 Three Months Ended December 31,
 Twelve Months Ended December 31,
  2018   2017   2018   2017 
Revenue       
Orthopedic product sales$18,192  $19,528  $71,814  $82,513 
Other revenue 70   (196)  389   99 
Total revenue 18,262   19,332   72,203   82,612 
        
Cost of Sales 11,006   9,039   28,717   32,511 
Inventory Reserve (4,378)  (2,199)  (4,378)  (2,199)
Adjusted Total Cost of Sales 6,628   6,840   24,339   30,312 
        
Adjusted Gross profit 11,634   12,492   47,864   52,300 
        
Gross profit % 63.7%  64.6%  66.3%  63.3%
        
Operating expenses       
General and administrative 3,330   3,260   12,881   15,246 
Sales and marketing 7,317   9,474   32,059   40,511 
Research and development 523   598   1,702   2,441 
Depreciation and amortization 1,044   1,381   4,118   5,485 
Goodwill & Intangible Asset impairment 48,146   17,586   48,146   17,586 
Reverse impairment charges (48,146)  (17,586)  (48,146)  (17,586)
Restructuring expenses 435   4,680   2,970   4,680 
Separation related expenses 1,078   505   1,568   1,901 
Non-cash consulting expense 108   (132)  120   85 
Total Adjusted Operating Expenses 13,835   19,766   55,418   70,349 
        
Loss from operations (2,201)  (7,274)  (7,554)  (18,049)
        
Other Income (Expense)       
Interest expense (1,990)  (4,166)  (10,145)  (14,705)
Change in warrant derivative liability 38   65   121   203 
Other (expense) income (14)  2,740   3   (75)
Total Other (Expense) Income (1,966)  (1,361)  (10,021)  (14,577)
        
Adjusted Net Loss$(4,167) $(8,635) $(17,575) $(32,626)
        
Net loss per share:       
Basic$(0.32) $(5.70) $(1.50) $(21.64)
Dilutive$(0.32) $(5.70) $(1.50) $(21.64)
        
Shares used in the computation:       
Basic 13,158,326   1,514,501   11,740,550   1,507,769 
Dilutive 13,158,326   1,514,501   11,740,550   1,507,769